Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Controlling spending in your 20s comes down to consistent routines: track, limit impulse buys, and automate saving to reinforce discipline.
21,066 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
New risk signals emerge as the S&P 500 grows more concentrated. Top 10 names and chipmakers now drive most of the mar...
Treasury yields are climbing, sending ripples through equities. This piece breaks down why rates are rising, who’s af...
If the market sinks tomorrow, one AI stock stands out as a compelling buy due to a durable moat, strong cash flow, an...
Think AI stocks can’t deliver both growth and income? This piece reveals two surprising dividend plays that tap AI tr...
As AI data centers surge, the choice between Constellation Energy and Vistra hinges on reliability, cost, and market ...
When a CEO discloses a sale of 41,600 shares, investors pay attention. This article unpacks the implications, the mec...
Jennifer Garner faced a pivotal choice: take a four-month filming commitment or stay close to home for her kids. This...
UnitedHealth stock has lagged in 2026, raising questions about its earnings, growth, and risks. This deep-dive breaks...
If you were starting over in real estate today, what would you do differently? This guide outlines five essential mov...
I recently allocated just more than $10,000 across three tech stocks to balance growth with risk. Here’s how I chose ...
The phrase oklo stock sinking today captures the mood around Oklo’s latest earnings and market reaction. This guide b...